Actively Recruiting
The Effect of Echinacea (Immulant ®) in the Treatment of CRYPTOSPORIDIOSIS in Immunocompromised Children
Led by Al-Azhar University · Updated on 2026-02-05
60
Participants Needed
1
Research Sites
27 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to: 1. To evaluate the effectiveness of Immulant ® addition to standard treatment in reducing clinical symptoms of Cryptosporidiosis in immunocompromised children. 2. To measure the changes in parasite count in stool samples after treatment with Immulant ®. 3. To assess the safety and tolerability of Immulant ® in children participating in the study.
CONDITIONS
Official Title
The Effect of Echinacea (Immulant ®) in the Treatment of CRYPTOSPORIDIOSIS in Immunocompromised Children
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinical diagnosis of Cryptosporidiosis Disease
- Age from 5-12 years
- Immunocompromised children
- Not receiving any drugs causing immunosuppression
You will not qualify if you...
- Patients undergoing organ transplantation
- Patients suffering from autoimmune diseases.
- Patients suffering from hypersensitivity of this plant extract
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Nutritional Institute
Cairo, Egypt, 11731
Actively Recruiting
Research Team
S
Salah
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here